The purpose of this study is to investigate the efficacy of BAI Plus 3DCRT in local advanced NSCLC.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
80
The 3rd Affiliated Hospital of the 3rd Military Hospital
Chongqing, China
RECRUITINGProgression Free Survival
Regular tumour assessments (based on RECIST criteria) for determining disease response and progression using CT and MRI scans, and overall survival.The primary efficacy variable is progression free survival (PFS), defined as the time between randomisation and the date of first documented disease progression or death from any cause, whichever comes first. Disease progression is defined according to the RECIST criteria.
Time frame: every 2 cycles
Overall Survival
after Progressive Disease, patient will be contact every 3 month for the survival information.
Time frame: every 3 month after Progressive Disease
Time to Progressive Disease (RECIST Criteria)
Regular tumour assessments (based on RECIST criteria) for determining disease response and progression using CT and MRI scans.Time to Progression (TTP) is defined as the time between randomisation and the date of the first documented disease progression.
Time frame: Every 2 cycles
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Drug: Gemcitabine, Nedaplatin, iV Gemcitabine, Injection, 1000mg/m2, D1/4weeks/cycle, 2 cycles Nedaplatin, Injection, 75mg/m2, d1/4weeks/cycle, 2 cycles. BAI